{"prompt": "['Novartis', 'Confidential', 'Page 57', 'Amended Protocol Version v02/Clean', 'Protocol No. CQVM149B2306', '7.2.2 SAE reporting', 'To ensure patient safety, every SAE, regardless of causality, occurring after the patient has', 'provided informed consent and until 30 days after the last study visit must be reported to', 'Novartis safety within 24 hours of learning of its occurrence. Any SAEs experienced after the', '30 day period after the last study visit should only be reported to Novartis safety if the', 'investigator suspects a causal relationship to study treatment.', 'All follow-up information for the SAE including information on complications, progression of', 'the initial SAE and recurrent episodes must be reported as follow-up to the original episode', 'within 24 hours of the investigator receiving the follow-up information. A SAE occurring at a', 'different time interval or otherwise considered completely unrelated to a previously reported', 'one must be reported separately as a new event.', 'Information about all SAEs is collected and recorded on the Serious Adverse Event Report', 'Form; all applicable sections of the form must be completed in order to provide a clinically', 'thorough report. The investigator must assess the relationship of each SAE to each specific', 'component of study treatment, complete the SAE Report Form in English, and submit the', 'completed form within 24 hours to Novartis. Detailed instructions regarding the submission', 'process and requirements for signature are to be found in the investigator folder provided to', 'each site.', 'Follow-up information is submitted as instructed in the investigator folder. Each re-', 'occurrence, complication, or progression of the original event must be reported as a follow-up', 'to that event regardless of when it occurs. The follow-up information should describe whether', 'the event has resolved or continues, if and how it was treated, whether the blind was broken or', 'not, and whether the patient continued or withdrew from study participation.', \"If the SAE is not previously documented in the Investigator's Brochure or Package Insert\", '(new occurrence) and is thought to be related to the study treatment a Drug Safety and', 'Epidemiology Department associate may urgently require further information from the', 'investigator for health authority reporting. Novartis may need to issue an Investigator', 'Notification (IN) to inform all investigators involved in any study with the same study', 'treatment that this SAE has been reported. Suspected Unexpected Serious Adverse Reactions', '(SUSARs) will be collected and reported to the competent authorities and relevant ethics', 'committees in accordance with EU Guidance 2011/C 172/01 or as per national regulatory', 'requirements in participating countries.', '7.3', 'Liver safety monitoring', 'To ensure patient safety and enhance reliability in determining the hepatotoxic potential of an', 'investigational drug, a standardized process for identification, monitoring and evaluation of', 'liver events has to be followed.', 'The following two categories of abnormalities/adverse events have to be considered during', 'the course of the study (irrespective of whether classified/reported as (S)AE):', 'Liver laboratory triggers, which will require repeated assessments of the abnormal', 'laboratory parameter']['Novartis', 'Confidential', 'Page 58', 'Amended Protocol Version v02/Clean', 'Protocol No. CQVM149B2306', 'Liver events, which will require close observation, follow-up monitoring and completion', 'of the standard base liver CRF pages', 'Please refer to Appendix 1 for complete definitions of liver laboratory triggers and liver', 'events.', 'Every liver laboratory trigger or liver event as defined in Appendix 1 should be followed up', 'by the investigator or designated personal at the trial site as summarized below. Detailed', 'information is outlined in Table 13-1 Liver Event and Laboratory Trigger Definitions.', 'For the liver laboratory trigger:', 'Repeating the liver function test (LFT) within the next week to confirm elevation.', 'The repeat of LFTs must be performed using the central laboratory, if possible. If this is not', 'possible, then the repeats can be performed at a local laboratory to monitor the safety of the', 'patient. If a liver event is subsequently reported, any local LFTs previously conducted that are', 'associated with this event must be reported on the Liver CRF pages.', 'If the elevation is confirmed, close observation of the patient will be initiated, including', 'consideration of treatment interruption if deemed appropriate.', 'For the liver events:', 'Repeating the LFT to confirm elevation as appropriate', 'Discontinuation of the investigational drug if appropriate', 'Hospitalization of the patient if appropriate', 'A causality assessment of the liver event via exclusion of alternative causes (e.g., disease,', 'co-medications)', 'An investigation of the liver event which needs to be followed until resolution.', 'These investigations can include serology tests, imaging and pathology assessments,', \"hepatologist's consultancy, based on investigator's discretion. All follow-up information, and\", 'the procedures performed must be recorded on appropriate eCRF pages, including the liver', 'event overview eCRF pages.', '7.4', 'Reporting of study treatment errors including misuse/abuse', 'Medication errors are unintentional errors in the prescribing, dispensing, administration or', 'monitoring of a medicine while under the control of a healthcare professional, patient or', 'consumer (EMA definition).', \"Medication errors are usually unintentional, although a patient can intentionally 'commit' a\", 'medication error due to a lack of medical knowledge or sound judgment (e.g. intentionally', 'removing drug from capsule and dissolving in juice) or there is an accidental drug omission', 'by an HCP). Medication errors are not considered to be misuse or abuse.', 'Misuse refers to situations where the medicinal product is intentionally and inappropriately', 'used not in accordance with the protocol.', 'Abuse corresponds to the persistent or sporadic, intentional excessive use of a medicinal', 'product, which is accompanied by harmful physical or psychological effects.']\n\n###\n\n", "completion": "END"}